Immunologic Factors: all 3,292 studies that test it
Page 1 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingNCT07892027Phase 2
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingNCT07889362Phase 2
- Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBTNot yet recruitingNCT07885982Phase 2
- Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus IsoimmunizationRecruitingNCT07885592Phase 2
- Stopping Strep Throat With Antibodies in Healthy Adults.Not yet recruitingNCT07864350Phase 1
- Population PK-guided ATG Dosing for Haploidentical Hematopoietic Stem Cell TransplantationRecruitingNCT07862127Phase 3
- Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous NephropathyRecruitingNCT07861204Phase 2/3
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingNCT07839247Phase 2
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung DiseaseNot yet recruitingNCT07827742Phase 2
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 2
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 2
- Population PK-guided ATG Dosing in Haplo-HSCTRecruitingNCT07791576Phase 2
- Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk OsteosarcomaRecruitingNCT07787429Phase 2
- Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus VulgarisNot yet recruitingNCT07769333Early Phase 1
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
- Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingNCT07760610Phase 4
- Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07757412Phase 2
- Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell LymphomaNot yet recruitingNCT07754682Phase 3
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingNCT07749365Phase 2
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
- Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingNCT07731789Phase 2
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldRecruitingNCT07722546Phase 2
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingNCT07719855Phase 3
- Efficacy and Safety of Lenalidomide in Patients With IgG4-Related DiseaseNot yet recruitingNCT07719543Phase 3
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Phase 4
- A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07703657Not applicable
- Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07698080Phase 2
- Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse EventsRecruitingNCT07694414Phase 1
- Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07693881Not applicable
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingNCT07677813Phase 2
- Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in ChildrenNot yet recruitingNCT07675291Not applicable
- Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary FibrosisNot yet recruitingNCT07674745Phase 2
- Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone LymphomaNot yet recruitingNCT07654465Phase 2
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell TransplantationRecruitingNCT07648992Phase 4
- Treatment Strategy for Patients With RA-ILDNot yet recruitingNCT07643038Phase 4
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingNCT07639138Phase 2
- Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaNot yet recruitingNCT07614282Phase 1
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingNCT07609719Phase 4
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingNCT07608731Phase 1
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- Haplo-Cord HSCT for AML/MDSRecruitingNCT07588360Not applicable
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
- A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingNCT07582432Phase 3
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07578077Phase 1/2
- Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and BelowRecruitingNCT07561125Phase 2
- A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person SyndromeNot yet recruitingNCT07552987Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT07540221Phase 3
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingNCT07532525Phase 1
- Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07523737Phase 2
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingNCT07517185Phase 2
- Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian InsufficiencyRecruitingNCT07509840Phase 3
- Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingRecruitingNCT07485647Phase 2
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingNCT07477366Phase 2
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07460362Phase 2
- Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Not yet recruitingNCT07451847Phase 4
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
- A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)Enrolling by invitationNCT07444489Phase 3
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingNCT07415980Phase 1/2
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
- Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot yet recruitingNCT07389356Not applicable
- Combining Latency Reversing Agents to Address the HIV ReservoirNot yet recruitingNCT07384624Phase 1/2
- Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 2
- A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Phase 2
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisRecruitingNCT07299695Phase 3
- Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaRecruitingNCT07285590Phase 2
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
- Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07269639Phase 1/2
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNCT07257510Not applicable
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaRecruitingNCT07257419Phase 1
- Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyRecruitingNCT07257055Phase 2
- Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLRecruitingNCT07255963Phase 2
- The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical StudyRecruitingNCT07240194Phase 2
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingNCT07224100Phase 2
- SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasRecruitingNCT07222631Phase 1/2
- A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationRecruitingNCT07219043Phase 2
- Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGRecruitingNCT07216391Phase 2
- Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingNCT07208981Phase 2
- Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaRecruitingNCT07206823Not applicable
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)RecruitingNCT07202091Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)RecruitingNCT07202078Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)RecruitingNCT07202065Phase 2/3